Xolair (omalizumab) - Roche, Novartis
Hereditary α-tryptasemia is associated with response to omalizumab in severe allergic asthma. (PubMed, Ann Allergy Asthma Immunol) - Oct 16, 2026 - "HαT is associated with poorer clinical response to anti-IgE treatment in patients with severe allergic asthma." 
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • TPSAB1
http://www.ncbi.nlm.nih.gov/pubmed/42880632
 
Clair Barber; Elena Vorobeva; Hans Michael Haitchi; Jonathan J Lyons; Julij Šelb; Manca Svetina; Matija Rijavec; Mihaela Zidarn; Nikki Graham; Peter Korošec; Ramesh J Kurukulaaratchy; Sabina Škrgat
 
Oct 16, 2026
 
Prev Next